Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753172 | 0.91 | USP2 (0.43) | USP2ALOX15KMT2APOLBSLC2A1 | |
| SCHEMBL21758435 | 0.87 | HTR1A (0.46) | USP2ALOX15KMT2APOLBSLC2A1 | |
| SCHEMBL21758302 | 0.85 | USP2 (0.44) | USP2ALOX15KMT2APOLBSLC2A1 | |
| SCHEMBL21753194 | 0.85 | GLA (0.48) | USP2ALOX15KMT2APOLBSLC2A1 | |
| SCHEMBL25378084 | 0.84 | CDK2 (0.45) | USP2ALOX15KMT2APOLBSLC2A1 | |
| SCHEMBL21758438 | 0.83 | BCHE (0.43) | USP2ALOX15KMT2APOLBSLC2A1 | |
| SCHEMBL23992004 | 0.83 | USP2 (0.45) | USP2KMT2AGPR18LMNAMAPT | |
| SCHEMBL21758310 | 0.83 | BCHE (0.42) | USP2ALOX15KMT2AHRH3GPR18 | |
| SCHEMBL21753176 | 0.82 | GBA1 (0.46) | USP2ALOX15KMT2AGPR18LMNA | |
| SCHEMBL31297706 | 0.82 | GBA1 (0.46) | USP2ALOX15KMT2AGPR18LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-02-11 | — | — | US | disclosed |
| EP-3841102-B1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2022-09-14 | — | — | EP | disclosed |
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-10-28 | — | — | US | disclosed |
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-10-28 | — | — | US | disclosed |
| CN-112739698-A | Tetrahydropyrimidine derivatives as AHR modulators | 捷豹治疗有限公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020039093-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | AHR, ARNT, NQO1 | USP2 2372/4885ALOX15 485/4885KMT2A 890/4885 |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | AHR, ARNT, NQO1 | USP2 2372/4885ALOX15 485/4885KMT2A 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.